Combination therapy for liver cancer that spread to lungs
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two oral medicines (camrelizumab and rivoceranib) along with local treatments like surgery or radiation for people whose liver cancer has spread to the lungs. The goal is to see if this approach can shrink the lung spots and help you live better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your liver cancer must be confirmed by biopsy or imaging, and it must have spread only to your lungs with 5 or fewer spots that haven't been treated yet.
- You must not have had any previous cancer-fighting medicines for your liver cancer (like chemotherapy or targeted pills).
- Your liver function should be fairly good (Child-Pugh score of 7 or less) and you should be physically active (able to care for yourself).
- Your blood counts, kidney function, and blood clotting should be within a safe range, as tested by lab work.
- If you have hepatitis B, you need to be willing to take antiviral medicine during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of treatments for people with liver cancer that can be surgically removed. The goal is to see if the combination helps shrink tumors and improve outcomes before surgery.
This study tests whether combining radiation therapy with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—can shrink liver cancer that has spread into the main portal vein. It’s for people with advanced liver cancer who haven’t had any systemic treatment before.
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
This trial tests a combination of two drugs (camrelizumab and apatinib) with or without standard chemotherapy for advanced liver cancer that cannot be treated with surgery or has gotten worse after local treatments. The goal is to see if the combination helps control the cancer better.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Hear when a new Hepatecellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.